Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Carlsson, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carlsson, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Drug-induced torsade de pointes: the perspectives of industry

L. Carlsson*

Integrative Pharmacology, AstraZeneca Research & Development Mölndal, Sweden

* Correspondence: Leif Carlsson, PhD, AstraZeneca Research & Development Mölndal, Integrative Pharmacology, S-431 83 Mölndal, Sweden.

Abstract

The appearance of QT prolongation and torsades de pointes during drug treatment is often unpredictable and has been recognised as a potential risk during treatment with antiarrhythmic as well as non-antiarrhythmic drugs. As a consequence, both regulatory bodies and the pharmaceutical industry are presently addressing the importance of early preclinical testing of novel compounds to identify QT prolongation and reassure safe clinical usage of new chemical entities. This paper briefly discusses some of the suggested in vitro methodologies and the predictive value of preclinical in vivo studies for assessment of repolarization delay of novel chemical entities.

Key Words: Drugs • action potential • repolarization • QT interval • torsade de pointes

References

  1. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997.
  2. Pourrias B, Porsolt RD, Lacroix P. QT interval prolongation by noncardiovascular drugs: a proposed assessment strategy. Drug Dev Res. 1999;47:55–62[CrossRef][Web of Science]
  3. Crumb W, Cavero I. QT interval prolongation by noncardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today. 1999;2:270–280[CrossRef][Medline]
  4. Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res. 2001;49:741–750[Abstract/Free Full Text]
  5. Haverkamp W, Breithardt G, Janse MJ, Camm AJ, Rosen MT. The potential for QT prolongation and proarrhythmia by non-antiarrhytmic drugs. Clinical and regulatory implications. Eur Heart J. 2000;: (in press)
  6. Wang Z, Fermini B, Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res. 1993;73:276–285[Abstract/Free Full Text]
  7. Verkerk AO, Veldkamp MW, Abbate F, et al. Two types of action potential configuration in single cardiac Purkinje cells of sheep. Am J Physiol. 1999;46:H1299–H1310
  8. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium. I. In vitro study. Circulation. 1997;96:4011–4018[Abstract/Free Full Text]
  9. Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther. 1996;276:637–646[Abstract/Free Full Text]
  10. Amos GJ, Abrahamsson C, Duker G, Mondeghem L, Palmer M, Carlsson L. Potassium and calcium current blocking properties of the novel antiarrythmic agent H 345/52: implications for proarrythmic potential. Cardiovasc Res. 2001;49:351–360[Abstract/Free Full Text]
  11. Noble D, Colatsky TJ. A return to rational drug discovery: computer-based models of cells, organs and systems in drug target identification. Emerging Therapeutic Targets. 2000;4:39–49
  12. Carmeliet E. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by doffetilide. J Pharmacol Exp Ther. 1992;62:809–817
  13. Bril A, Forest MC, Cheval B, Faivre IF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc Res. 1998;37:130–140[Abstract/Free Full Text]
  14. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686–690[Abstract/Free Full Text]
  15. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999;10:1124–1152[Web of Science][Medline]
  16. Abrahamsson C, Palmer M, Ljung B, et al. Induction of rhythm abnormalities in the fetal rat heart—A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res. 1994;28:337–344[Abstract/Free Full Text]
  17. Davis AS. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol. 1998;17:677–680[Abstract/Free Full Text]
  18. Sugiyama A, Aye NN, Katahira S, et al. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol. 1997;143:89–95[CrossRef][Web of Science][Medline]
  19. Adamantidis MM, Lacroix DL, Caron IF, Dupuis BA. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole in rabbit Purkinje fibers: clinical relevance. J Cardiovasc Pharmacol. 1995;26:319–327[Web of Science][Medline]
  20. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RE, Guinosso PJ Jr, Lynch JJ Jr. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995;76:110–119[Abstract/Free Full Text]
  21. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation. 1993;88:1832–1844[Abstract/Free Full Text]
  22. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother. 1996;37(Suppl A):161–167[Abstract/Free Full Text]
  23. Adamantidis MM, Dumotier BM, Caron IF, Border R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundamen Clin Pharmacol. 1998;12:70–76[Web of Science][Medline]
  24. Carlsson L, Amos G, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride — Implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282:220–227[Abstract/Free Full Text]
  25. Marshall FN. Pharmacology and toxicology of probucol. Artery. 1982;10:7–21[Web of Science][Medline]
  26. Natsukawa T, Matsuzaki T, Hayashi S, Ukai Y, Yoshikuni Y, Kimura K. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. Gen Pharmacol. 1998;30:137–142[Web of Science][Medline]
  27. Shuba LM, Kasamaki Y, Jones SE, Ogura T, McCullough JR, McDonald TF. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. J Pharmacol Exp Ther. 1999;290:1417–1426[Abstract/Free Full Text]
  28. Risperidone Summary Basis of Approval. New Drug Application 20-272. Food and Drugs Administration, Washington, DC.
  29. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol. 1998;18:477–481[CrossRef][Web of Science][Medline]
  30. Wysowski DK, Bacsanyi J, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335:290–291[Free Full Text]
  31. Axelsson R, Nilsson A, Christensson E, Björk A. Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychpharmacology. 1991;104:287–292
  32. Hui WK, Mitchell LB, Kavanagh KM, et al. Melperone: electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol. 1990;15:144–149[Web of Science][Medline]
  33. Faigel DO, Metz DC, Kochman ML. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol. 1995;90:822–824[Web of Science][Medline]
  34. Brown GR, Radford JM. Sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile. South Med J. 1997;90:691–693[CrossRef][Web of Science][Medline]
  35. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol. 1996;36:233–252[CrossRef][Web of Science][Medline]
  36. Hanley SP, Hampton JR. Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J. 1983;4:889–893[Abstract/Free Full Text]
  37. Aldariz AE, Romero H, Baroni M, Baglivo H, Esper RJ. QT prolongation and torsade de pointes ventricular tachycardia produced by ketanserin. Pacing Clin Electrophsiol. 1986;9:836–841[CrossRef]
  38. McLeod AA, Thorogood S, Barnett S. Torsades de pointes complicating treatment with terodiline. Br Med J. 1991;302:1469
  39. Rousseau ME, Massart PE, van Eyll C, et al. Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure. J Am Coll Cardiol. 1997;30:1751–1757[Abstract]
  40. Butrous GS, Debbas NM, Erwin J, et al. Clinical cardiac electrophysiologic evaluation of the positive isotropic agent, DPI 201-106. Eur Heart J. 1988;9:489–497[Abstract/Free Full Text]
  41. Browse KF, Prystowsky EN, Heger JJ, Cerimele BL, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. Am Heart J. 1984;107:680–684[CrossRef][Web of Science][Medline]
  42. Foster RH, Wilde MI, Markham A. Ibutilide—a review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997;54:312–330[Web of Science][Medline]
  43. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–865[Abstract/Free Full Text]
  44. Waldo AL, Camm AJ, et al, SWORD investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12[CrossRef][Web of Science][Medline]
  45. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Carlsson, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carlsson, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?